Literature DB >> 6290033

Differentiation of platelet-aggregating effects of human tumor cell lines based on inhibition studies with apyrase, hirudin, and phospholipase.

E Bastida, A Ordinas, S L Giardina, G A Jamieson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6290033

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  18 in total

1.  Addition of both platelets and thrombin in combination accelerates tumor cells to adhere to endothelial cells in vitro.

Authors:  I B Helland; B Klementsen; L Jørgensen
Journal:  In Vitro Cell Dev Biol Anim       Date:  1997-03       Impact factor: 2.416

2.  Role of von Willebrand factor in tumour cell-induced platelet aggregation: differential regulation by NO and prostacyclin.

Authors:  P Jurasz; M W Stewart; A Radomski; F Khadour; M Duszyk; M W Radomski
Journal:  Br J Pharmacol       Date:  2001-11       Impact factor: 8.739

3.  Characterization of platelet aggregation induced by human breast carcinoma and its inhibition by snake venom peptides, trigramin and rhodostomin.

Authors:  H S Chiang; M W Swaim; T F Huang
Journal:  Breast Cancer Res Treat       Date:  1995-03       Impact factor: 4.872

4.  Involvement of a cathepsin B-like cysteine proteinase in platelet aggregation induced by tumor cells and their shed membrane vesicles.

Authors:  P G Cavanaugh; B F Sloane; A S Bajkowski; G J Gasic; T B Gasic; K V Honn
Journal:  Clin Exp Metastasis       Date:  1983 Oct-Dec       Impact factor: 5.150

Review 5.  Role of plasma, platelets, and endothelial cells in tumor metastasis.

Authors:  G J Gasic
Journal:  Cancer Metastasis Rev       Date:  1984       Impact factor: 9.264

6.  Activated platelets enhance ovarian cancer cell invasion in a cellular model of metastasis.

Authors:  C E Holmes; J E Levis; D L Ornstein
Journal:  Clin Exp Metastasis       Date:  2009-05-15       Impact factor: 5.150

7.  FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal.

Authors:  Monika Haemmerle; Justin Bottsford-Miller; Sunila Pradeep; Morgan L Taylor; Hyun-Jin Choi; Jean M Hansen; Heather J Dalton; Rebecca L Stone; Min Soon Cho; Alpa M Nick; Archana S Nagaraja; Tony Gutschner; Kshipra M Gharpure; Lingegowda S Mangala; Rajesha Rupaimoole; Hee Dong Han; Behrouz Zand; Guillermo N Armaiz-Pena; Sherry Y Wu; Chad V Pecot; Alan R Burns; Gabriel Lopez-Berestein; Vahid Afshar-Kharghan; Anil K Sood
Journal:  J Clin Invest       Date:  2016-04-11       Impact factor: 14.808

8.  Platelet interaction with a pancreatic ascites tumor.

Authors:  J Hamilton; V Subbarao; K Granack; C Ts'ao
Journal:  Am J Pathol       Date:  1986-01       Impact factor: 4.307

9.  Tumor cell-platelet interactions in vitro and their relationship to in vivo arrest of hematogenously circulating tumor cells.

Authors:  D G Menter; J S Hatfield; C Harkins; B F Sloane; J D Taylor; J D Crissman; K V Honn
Journal:  Clin Exp Metastasis       Date:  1987 Jan-Mar       Impact factor: 5.150

Review 10.  Interaction between circulating cancer cells and platelets: clinical implication.

Authors:  Xiao-Liang Lou; Jian Sun; Shu-Qi Gong; Xue-Feng Yu; Rui Gong; Huan Deng
Journal:  Chin J Cancer Res       Date:  2015-10       Impact factor: 5.087
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.